Drugs / LY4057996
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06945406 | May 2025 → Dec 2026 expected | type 1 diabetes mellitus, type 2 diabetes mellitus | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4057996 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06945406 ↗ |
| Route | Subcutaneous | “Administered SC” NCT06945406 ↗ |